Skip to Content
  • You Ask For It; You Get It

    So Valeant is getting rid of their CEO, the not-so-beloved Michael Pearson, and has started to come clean about accounting problems at the company. This stateme… Read More
  • Chemical Evolution Makes a Deal

    Sanofi has signed a deal with a Stanford-born startup called DiCE Molecules, looking for small-molecule inhibitors of protein-protein interactions. So who are t… Read More
  • Valeant Implodes

    You might have noticed what happened to Valeant Pharmaceuticals yesterday. I was traveling and unable to blog about it during the afternoon, but it was quite a… Read More
  • Getting It Done Here – Or Not

    Outsourcing of chemistry is not quite the hot-button issue it was a few years ago, but it’s still very much with us. All sorts of US firms get work done i… Read More
  • A (Busy) Day in the Life

    I’d like to recommend this article by Lisa Jarvis at C&E News – she’s following along with Forge Therapeutics, a small startup specializin… Read More
  • Inhaled Insulin Strikes (Out) Again

    The Wall Street Journal has a good post-mortem of Sanofi’s inhaled insulin experience with Mannkind. I was puzzled by that deal when it was announced, bec… Read More
  • Compassion, Drug Prices, and Money

    A number of people have sent along this article from The Guardian. It’s about Jamie Love, a campaigner for cheaper pharmaceuticals. It’s a long, wel… Read More
Page 10 of 104« First...89101112...203040...Last »